In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

For Shire, Life After Adderall XR? Yes

Executive Summary

Shire has scaled its Adderall XR patent cliff, replenishing lost blockbuster sales with revenues from niche products, smart life-cycle management, and some good-old-fashioned luck. IN VIVO interviews CEO Angus Russell.
Advertisement

Related Content

Shire CEO Angus Russell On The Value Proposition For Drugs
Sanofi And Genzyme: Do Big Pharmas And Orphan Drugs Fit Together?
Sanofi And Genzyme: Do Big Pharmas And Orphan Drugs Fit Together?
Genzyme's Manufacturing Problems
Genzyme's Manufacturing Problems
Shire Shuffles Corporate Leadership: CFO Russell Rises To CEO
Shire: Remodeling Specialty Pharma
Shire: Remodeling Specialty Pharma

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

IV003510

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel